RxDoctor Payments Data

Mark Butler, MD

Family Medicine · Lincoln, NENPI 1396847984

Payments from drug & device makers

$8,290in general payments, 2019–2025

Across 494 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$671
  • Aimmune Therapeutics, Inc.$582
  • Amgen$575
  • Novo Nordisk$521
  • AstraZeneca$491
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$8,274100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,290 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$166,699
Medicare patients
304
Services billed
6,652

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban40$31,999
TrulicityDulaglutide25$30,892
XareltoRivaroxaban30$29,246
JardianceEmpagliflozin15$23,359
FarxigaDapagliflozin Propanediol28$20,036
MyrbetriqMirabegron26$19,566
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,189
LinzessLinaclotide18$16,925
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$5,472
Humalog Kwikpen U-100Insulin Lispro11$3,485
Atorvastatin Calcium501$3,121
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm12$2,985
Levothyroxine Sodium351$2,875
Omeprazole195$2,557
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$671$31,99940 claims
Lilly USA, LLCTrulicity$420$30,89225 claims
Johnson & JohnsonXarelto$184$29,24630 claims
Boehringer IngelheimJardiance$149$23,35915 claims
AstraZenecaFarxiga$491$20,03628 claims
Astellas Pharma US IncMyrbetriq$379$19,56626 claims
GSKTrelegy Ellipta$69$18,18929 claims
AbbVieLinzess$1,731$16,92518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →